In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

IQVIA Holdings Inc.

https://www.iqvia.com/

Latest From IQVIA Holdings Inc.

Asia Deal Watch: invoX Builds Novel Pipeline Through $161m F-star Acquisition

F-star's novel bispecific technology attracts Sino Biopharma-affiliated acquisition, Shionogi agreement with GARDP brings antibiotic cefiderocol to 135 countries, deal with WinHealth covering Greater China expands Quoin’s licensing of Netherton syndrome candidate to 60 nations, Kyorin and CellGenTech team up in Fabry disease.

Deal Watch Business Strategies

Alzheimer’s Evidence Accelerator Modeled On FDA COVID Project Floated By USAgainstAlzheimer’s

Patient organization exploring development of a multi-stakeholder forum on real world evidence that, among other things, could address research questions posed by the Centers for Medicare and Medicaid Services in its national coverage determination for Alzheimer’s drugs.

Reimbursement Real-World Evidence

Ukraine War Could Spur Changes In The Clinical Trial Paradigm

Decentralized trials are a way to help displaced Ukrainians remain in studies and could encourage greater participation from individuals in other countries, those overseeing sites in Ukraine say.

Clinical Trials Policy

COVID-19 Vaccine Trial Efficiencies, Leadership Alignment: What Can Be Carried Forward

Operational actions, organizational responses and clinical development model improvements led to a 26-month acceleration, on average, in a set of COVID-19 vaccine pivotal trials versus similarly sized pre-pandemic studies, with the database lock and analysis stage delivering dramatic gains, a study by IQVIA Institute indicates. Can these benefits be recapitulated across the portfolio in the post-pandemic era?

Research & Development Clinical Trials
See All

Company Information

  • Industry
  • Contract Research Organization-CRO
  • Services
  • Other Names / Subsidiaries
    • Quintiles
    • IMS Health, IQVIA Biotech LLC, Novasyte, LLC
    • Myriad RBM Inc.
UsernamePublicRestriction

Register